Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are mainstays of cancer treatment. However, their clinical benefits are often constrained by acquired resistance. To overcome such outcomes, we have rationally engineered APG-2449 as a novel multikinase inhibitor that is highly potent against oncogenic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Douglas D., Tao, Ran, Wang, Guangfeng, Li, Yuanbao, Zhang, Kaixiang, Xu, Chunhua, Zhai, Guoqin, Wang, Qixin, Wang, Jingwen, Tang, Chunyang, Min, Ping, Xiong, Dengkun, Chen, Jianyong, Wang, Shaomeng, Yang, Dajun, Zhai, Yifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277925/
https://www.ncbi.nlm.nih.gov/pubmed/35820889
http://dx.doi.org/10.1186/s12885-022-09799-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277925/
https://www.ncbi.nlm.nih.gov/pubmed/35820889
http://dx.doi.org/10.1186/s12885-022-09799-4

Ejemplares similares